- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.05. | Boundless Bio GAAP EPS of -$0.60 | 2 | Seeking Alpha | ||
| 08.05. | Boundless Bio, Inc.: Boundless Bio Reports First Quarter 2026 Financial Results and Business Highlights | 187 | GlobeNewswire (Europe) | Enrollment proceeding in KOMODO-1 first-in-human clinical trial of BBI-940 $93 million in cash provides runway through expected clinical proof-of-concept readout for KOMODO-1 SAN DIEGO, May 08, 2026... ► Artikel lesen | |
| 08.05. | Boundless Bio, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 08.05. | Boundless Bio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 17.04. | Boundless Bio presents preclinical data on cancer therapy BBI-940 | 2 | Investing.com | ||
| 17.04. | Boundless Bio, Inc.: Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting | 2 | GlobeNewswire (USA) | ||
| 13.04. | Boundless Bio, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| BOUNDLESS BIO Aktie jetzt für 0€ handeln | |||||
| 17.03. | Boundless Bio, Inc.: Boundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026 | 1 | GlobeNewswire (USA) | ||
| 10.03. | Leerink reiterates Market Perform on Boundless Bio stock at $4 | 4 | Investing.com | ||
| 10.03. | Boundless Bio: Leerink bestätigt "Market Perform"-Rating und Kursziel von 4 US-Dollar | 3 | Investing.com Deutsch | ||
| 09.03. | Boundless Bio verringert Quartalsverlust und übertrifft Analystenerwartungen | 2 | Investing.com Deutsch | ||
| 09.03. | Boundless Bio GAAP EPS of -$0.58 misses by $0.12 | 1 | Seeking Alpha | ||
| 09.03. | Boundless Bio, Inc.: Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights | 654 | GlobeNewswire (Europe) | KOMODO-1 first-in-human clinical trial of BBI-940 open for enrollment $108 million in cash provides runway into the second half of 2028, through expected clinical proof-of-concept readout for KOMODO-1... ► Artikel lesen | |
| 09.03. | Boundless Bio, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 09.03. | Boundless Bio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 05.02. | Boundless Bio, Inc.: Boundless Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 | 5 | GlobeNewswire (USA) | ||
| 20.01. | Boundless Bio, Inc.: Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway | 2 | GlobeNewswire (USA) | ||
| 23.05.25 | Boundless Bio, Inc.: Boundless Bio Announces Portfolio Prioritization and Runway Extension | 450 | GlobeNewswire (Europe) | Portfolio prioritization focuses on novel-novel combination therapy of BBI-355 and BBI-825 and new development candidate, BBI-940, for novel kinesin program Operating runway extended into the first... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 76,40 | -2,98 % | BioNTech-Krise vs. Emyria-Durchbruch? Warum Daten jetzt die Forschung schlagen | ||
| EVOTEC | 4,618 | -1,74 % | KURSRUTSCH bei Nel ASA und Evotec! KURSCHANCE bei HPQ Silicon! | Steht die Aktie von HPQ Silicon vor einer Neubewertung? Dafür gibt es jedenfalls gute Gründe. Die Hochleistungsbatterien haben erneut überzeugt. Damit könnte für Anwendungen in Drohnen, Verteidigung... ► Artikel lesen | |
| AMGEN | 282,15 | +0,46 % | Dividendenbekanntmachungen (15.05.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A10 NETWORKS INC US0021211018 0,06 USD 0,0514 EUR AF GRUPPEN ASA NO0003078107 6,5 NOK 0,6029 EUR AGCO CORPORATION US0010841023 0... ► Artikel lesen | |
| NOVAVAX | 7,800 | 0,00 % | Novavax Stock Is Red Hot but the Smart Money Is Slamming on the Brakes | ||
| BIOGEN | 165,76 | -0,16 % | Biogen Inc.: Biogen Completes Acquisition of Apellis Pharmaceuticals | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the successful completion of the acquisition of Apellis Pharmaceuticals, Inc. (Nasdaq: APLS). Apellis... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 14,990 | +2,11 % | PALATIN TECHNOLOGIES INC - 10-Q, Quarterly Report | ||
| VIVOSIM LABS | 1,300 | +0,78 % | VivoSim Labs, Inc.: VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales | SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,178 | +4,90 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports First Quarter 2026 Financial Results and Recent Business Highlights | Biologics License Application (BLA) for INO-3107 actively being reviewed under the accelerated approval program by the U.S. Food and Drug Administration (FDA)... ► Artikel lesen | |
| VIKING THERAPEUTICS | 26,400 | +1,15 % | Viking Therapeutics, Inc.: Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | Conference call scheduled for 4:30 p.m. ET today
-- Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Advance; VANQUISH-1 and VANQUISH-2 Trials Fully Enrolled... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 11,580 | -1,53 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates | Presented positive Phase 3 HAELO topline clinical data for lonvo-z in HAE; initiated rolling BLA submission; anticipate U.S. launch in first half of 2027Recently resumed patient screening in MAGNITUDE... ► Artikel lesen | |
| TEMPUS AI | 37,820 | +0,11 % | Tempus AI, Bristol Myers Squibb Expand AI-Driven Clinical Trial Efforts | ||
| BIOCRYST PHARMACEUTICALS | 7,912 | +1,88 % | BioCryst Ireland, a Neopharmed Gentili company: Hereditary angioedema, a European initiative to shine a spotlight on a still under-recognized condition | Ahead of World HAE Day, BioCryst Ireland, a Neopharmed Gentili company, organised an international event in Milan bringing together leading experts from across Europe to raise awareness of... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 45,340 | +1,66 % | BioMarin stock price target raised to $110 by Freedom Broker | ||
| ABIVAX | 100,00 | +0,86 % | EQS-News: ABIVAX: Abivax Announces Results of its May 11, 2026 Annual General Meeting | EQS-News: ABIVAX
/ Key word(s): AGM/EGM
Abivax Announces Results of its May 11, 2026 Annual General Meeting
11.05.2026 / 22:05 CET/CEST
The issuer is solely responsible... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 15,240 | +0,93 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG |
Das Unternehmen BOUNDLESS BIO INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +1,34 % bei einem Aktienkurs von 1,510 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BOUNDLESS BIO INC finden Sie auf Wallstreet Online.